polatuzumab vedotin in previouslyuntreated diffuse large b-cell lymphoma.
Published 2 years ago • 923 plays • Length 43:40Download video MP4
Download video MP3
Similar videos
-
43:40
polatuzumab vedotin in previouslyuntreated diffuse large b-cell lymphoma
-
2:00
polatuzumab vedotin and car t-cell therapy for diffuse large b-cell lymphoma
-
1:15
polatuzumab vedotin combined with chemotherapy in untreated large b-cell lymphoma
-
4:56
catherine diefenbach: polatuzumab vedotin for follicular lymphoma
-
0:58
polatuzumab in diffuse large b-cell lymphoma
-
4:59
a breakthrough therapy: polatuzumab vedotin plus br for r/r dlbcl
-
2:07
dr. hou on polatuzumab vedotin in dlbcl
-
3:12
polarix: polatuzumab vedotin and r-chp superior to r-chop in dlbcl
-
2:54
updated results of glofitamab plus polatuzumab vedotin combination therapy in dlbcl, including hgbcl
-
4:25
phase ib polatuzumab vedotin trial
-
2:19
dr. kahl discusses polatuzumab vedotin in lymphoma
-
1:30
polatuzumab vedotin plus rituximab and lenalidomide in dlbcl: a phase ib/ii study
-
2:01
will newer therapies be curative for diffuse large b-cell lymphoma patients?
-
2:54
safety and efficacy of mosunetuzumab plus polatuzumab vedotin
-
3:13
treatment using mosunetuzumab with or without obinutuzumab and polatuzumab vedotin in fl and mzl
-
0:36
transplantation in ctcl
-
0:56
sunmo trial design: mosunetuzumab plus polatuzumab vedotin vs r-gemox in r/r nhl
-
5:46
glofitamab and polatuzumab vedotin in dlbcl
-
2:59
the polarix trial: polatuzumab with r-chp in dlbcl